AAAAAA

   
Results: 1-24 |
Results: 24
Tissue examination to monitor antiangiogenic therapy: A phase I clinical trial with endostatin
Authors: Mundhenke, C Thomas, JP Wilding, G Lee, FT Kelzc, F Chappell, R Neider, R Sebree, LA Friedl, A
Citation: C. Mundhenke et al., Tissue examination to monitor antiangiogenic therapy: A phase I clinical trial with endostatin, CLIN CANC R, 7(11), 2001, pp. 3366-3374
Identification of the prostate cancer micro-foci with chromosome 8p deletion at the tumor interface area by histopathological-FISH parallel examination
Authors: Wu, SQ Hafez, GR Zhang, JH Newton, M Chen, A Lange, J Wilding, G
Citation: Sq. Wu et al., Identification of the prostate cancer micro-foci with chromosome 8p deletion at the tumor interface area by histopathological-FISH parallel examination, INT J ONCOL, 19(6), 2001, pp. 1143-1147
Executive summary of the National Cancer Institute Workshop: Highlights and recommendations
Authors: Lieberman, R Nelson, WG Sakr, WA Meysken, FL Klein, EA Wilding, G Partin, AW Lee, JJ Lippman, SM
Citation: R. Lieberman et al., Executive summary of the National Cancer Institute Workshop: Highlights and recommendations, UROLOGY, 57(4A), 2001, pp. 4-27
Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents
Authors: Nelson, WG Wilding, G
Citation: Wg. Nelson et G. Wilding, Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents, UROLOGY, 57(4A), 2001, pp. 56-63
Prostate cancer prevention strategies using antiproliferative or differentiating agents
Authors: Walczak, J Wood, H Wilding, G Williams, T Bishop, CW Carducci, M
Citation: J. Walczak et al., Prostate cancer prevention strategies using antiproliferative or differentiating agents, UROLOGY, 57(4A), 2001, pp. 81-85
Angiogenesis inhibitors - New agents in cancer therapy
Authors: Ryan, CJ Wilding, G
Citation: Cj. Ryan et G. Wilding, Angiogenesis inhibitors - New agents in cancer therapy, DRUG AGING, 17(4), 2000, pp. 249-255
Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day
Authors: Ripple, GH Gould, MN Arzoomanian, RZ Alberti, D Feierabend, C Simon, K Binger, K Tutsch, KD Pomplun, M Wahamaki, M Marnocha, R Wilding, G Bailey, HH
Citation: Gh. Ripple et al., Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day, CLIN CANC R, 6(2), 2000, pp. 390-396
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies
Authors: Ochoa, L Hurwitz, HI Wilding, G Cohen, D Thomas, JP Schwartz, G Monroe, P Petros, WP Ertel, VP Hsieh, A Hoffman, C Drengler, R Magnum, S Rowinsky, EK
Citation: L. Ochoa et al., Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies, ANN ONCOL, 11(10), 2000, pp. 1313-1322
Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D-2) prostate cancer
Authors: Kasimis, B Wilding, G Kreis, W Feuerman, M Chang, V Hwang, S Steafather, H Cogswell, J Rae, C Blumenfrucht, M
Citation: B. Kasimis et al., Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D-2) prostate cancer, CANCER INV, 18(7), 2000, pp. 602-608
Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group study
Authors: Dreicer, R Manola, J Roth, BJ Cohen, MB Hatfield, AK Wilding, G
Citation: R. Dreicer et al., Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group study, J CL ONCOL, 18(5), 2000, pp. 1058-1061
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acidfor patients with advanced renal cell carcinoma
Authors: Motzer, RJ Murphy, BA Bacik, J Schwartz, LH Nanus, DM Mariani, T Loehrer, P Wilding, G Fairclough, DL Cella, D Mazumdar, M
Citation: Rj. Motzer et al., Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acidfor patients with advanced renal cell carcinoma, J CL ONCOL, 18(16), 2000, pp. 2972-2980
A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases- A case of fatal central nervous system thrombosis
Authors: Hotton, KM Khorsand, M Hank, JA Albertini, M Kim, KM Wilding, G Salamat, MS Larson, M Sondel, P Schiller, JH
Citation: Km. Hotton et al., A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases- A case of fatal central nervous system thrombosis, CANCER, 88(8), 2000, pp. 1892-1901
Low-dose difluoromethylornithine and polyamine levels in human prostate tissue
Authors: Messing, EM Love, RR Tutsch, KD Verma, AK Douglas, J Pomplun, M Simsiman, R Wilding, G
Citation: Em. Messing et al., Low-dose difluoromethylornithine and polyamine levels in human prostate tissue, J NAT CANC, 91(16), 1999, pp. 1416-1417
Effect of antioxidants on androgen-induced AP-1 and NF-kappa B DNA-bindingactivity in prostate carcinoma cells
Authors: Ripple, MO Henry, WF Schwarze, SR Wilding, G Weindruch, R
Citation: Mo. Ripple et al., Effect of antioxidants on androgen-induced AP-1 and NF-kappa B DNA-bindingactivity in prostate carcinoma cells, J NAT CANC, 91(14), 1999, pp. 1227-1232
Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial
Authors: Fields-Jones, S Koletsky, A Wilding, G O'Rourke, M O'Rourke, T Eckardt, J Yates, B McGuirt, C Burris, HA
Citation: S. Fields-jones et al., Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial, ANN ONCOL, 10(11), 1999, pp. 1307-1310
Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer
Authors: Robins, HI Tutsch, K Katschinski, DM Jacobson, E Mehta, M Olsen, M Cohen, JD Tiggelaar, CL Arzoomanian, RZ Alberti, D Feierabend, C Wilding, G
Citation: Hi. Robins et al., Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer, J CL ONCOL, 17(9), 1999, pp. 2922-2931
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
Authors: Bubley, GJ Carducci, M Dahut, W Dawson, N Daliani, D Eisenberger, M Figg, WD Freidlin, B Halabi, S Hudes, G Hussain, M Kaplan, R Myers, C Oh, W Petrylak, DP Reed, E Roth, B Sartor, O Scher, H Simons, J Sinibaldi, V Small, EJ Smith, MR Trump, DL Vollmer, R Wilding, G
Citation: Gj. Bubley et al., Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group, J CL ONCOL, 17(11), 1999, pp. 3461-3467
A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees Cwhole-body hyperthermia
Authors: Robins, HI Katschinski, DM Longo, W Grosen, E Wilding, G Gillis, W Kraemer, C Tiggelaar, CL Stewart, JA Spriggs, D Arzoomanian, RZ Feierabend, C Alberti, D Morgan, K Simon, K d'Oleire, F
Citation: Hi. Robins et al., A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees Cwhole-body hyperthermia, CANC CHEMOT, 43(5), 1999, pp. 409-414
A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer
Authors: Witte, RS Lipsitz, S Goodman, TL Asbury, RF Wilding, G Strnad, CM Smith, TJ Haller, DG
Citation: Rs. Witte et al., A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer, INV NEW DR, 17(2), 1999, pp. 173-177
Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812)
Authors: Tutsch, KD Arzoomanian, RZ Alberti, D Tombes, MB Feierabend, C Robins, HI Spriggs, DR Wilding, G
Citation: Kd. Tutsch et al., Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812), INV NEW DR, 17(1), 1999, pp. 63-72
Drug development in prostate cancer
Authors: Ripple, GH Wilding, G
Citation: Gh. Ripple et G. Wilding, Drug development in prostate cancer, SEMIN ONCOL, 26(2), 1999, pp. 217-226
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
Authors: Messing, EM Manola, J Sarosdy, M Wilding, G Crawford, ED Trump, D
Citation: Em. Messing et al., Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer, N ENG J MED, 341(24), 1999, pp. 1781-1788
Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice
Authors: Church, D Zhang, YL Rago, R Wilding, G
Citation: D. Church et al., Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice, CANC CHEMOT, 43(3), 1998, pp. 198-204
A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and or metastatic solid tumors
Authors: Berlin, JD Alberti, DB Arzoomanian, RZ Feierabend, CA Simon, KJ Binger, KA Marnocha, RM Wilding, G
Citation: Jd. Berlin et al., A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and or metastatic solid tumors, INV NEW DR, 16(4), 1998, pp. 325-330
Risultati: 1-24 |